Efficacy observation of primary chemotherapy combined with postoperative intraperitoneal hyperthermic perfusion chemotherapy for treatment of advanced ovarian cancer
10.3760/cma.j.issn.1006-9801.2018.06.006
- VernacularTitle:先期化疗联合术后腹腔热灌注化疗治疗晚期卵巢癌效果观察
- Author:
Pei WANG
1
;
Xiaohua ZHAO
;
Xiaoyan WANG
Author Information
1. 山西省肿瘤医院妇一科
- Keywords:
Ovarian neoplasms;
Antineoplastic combined chemotherapy protocols;
Intraperitoneal hyperthermic perfusion chemotherapy;
Postoperative complications;
Prognosis
- From:
Cancer Research and Clinic
2018;30(6):384-387
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical effects, complications and prognosis of primary chemotherapy combined with postoperative intraperitoneal hyperthermic perfusion chemotherapy in the treatment of advanced ovarian cancer. Methods The clinical data of 64 patients with advanced ovarian cancer in Shanxi Provincial Cancer Hospital from May 2015 to May 2017 were analyzed retrospectively. Conventional cytoreductive surgery (CDS) was performed in all patients. According to the different therapeutic regimen before and after operation, the patients were divided into 2 groups, including 32 cases treated with primary chemotherapy combined with postoperative intraperitoneal hyperthermic perfusion chemotherapy (the observation group), and 32 cases treated with intraperitoneal hyperthermic perfusion chemotherapy after operation (the control group). The clinical effect, complications and prognosis were compared between the two groups. Results The blood loss in the observation group [(512±165) ml] was lower than that in the control group [(815±186) ml]. The amount of ascites in the observation group [(716±160) ml ] was lower than that in the control group [(1 279±236) ml], and the differences were statistically significant (t= 6.890, t= 11.153 respectively, both P＜ 0.05). Moreover, the duration of surgery in the observation group was shorter than that in the control group [(125 ±15) min vs. (185 ±24) min; t = 18.572, P＜ 0.05]. The total incidence of complications and 2-year recurrence rate in the observation group were lower than those in the control group, and the 2-year survival rate in the observation group was higher than that in the control group (both P＜0.05). Conclusion Primary chemotherapy combined with postoperative intraperitoneal hyperthermic perfusion chemotherapy for advanced ovarian cancer has a favorable effect with less complications and good prognosis, which is worthy of clinical application.
